ENXTPA:SANPharmaceuticals
Sanofi (ENXTPA:SAN) Valuation Check After EMA Backing For Dupixent And Acoziborole
Regulatory momentum in immunology and infectious diseases
Sanofi (ENXTPA:SAN) is back in focus after European regulators issued positive opinions on two key therapies: Dupixent for pediatric chronic spontaneous urticaria and Acoziborole Winthrop for gambiense sleeping sickness.
For investors, these regulatory milestones highlight Sanofi’s progress in immunology and infectious diseases, areas that can shape long term portfolio perceptions, especially given the company’s established presence...